Introduction to Critical Care
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Speakers and Topics
SPEAKERS AND TOPICS SALZBURG WEILL CORNELL SEMINAR ANESTHESIOLOGY AND INTENSIVE CARE Sunday, October 18 – Saturday, October 24, 2020 Schloss Arenberg, Salzburg, Austria Course Director: Hugh C. Hemmings Jr., MD, PhD, FRCA Co-Course Director: Klaus Markstaller, MD Co-Course Director: Kane O. Pryor, MD Co-Course Director: Peter Marhofer, MD SPEAKERS AND TOPICS: Meghann M. Fitzgerald, MD Assistant Professor of Clinical Anesthesiology Weill Cornell Medical College Assistant Attending Anesthesiologist NewYork-Presbyterian Hospital Weill Cornell Medicine Anesthesiology New York, NY USA • Robotic Cardiac Surgery • Blood Management in Cardiac Surgery • TAAA Repair Lukas Kirchmair, MD, PD, DESA, EDRA Department of Anesthesiology and Intensive Care District Hospital Schwaz Schwaz Austria • Polytrauma Management Rudolf Likar, MD, MSc Professor Head, Department of Anesthesiology and Intensive Care General Hospital Klagenfurt Klagenfurt am Woerthersee Austria • Invasive Methods in Cancer Pain • Invasive Methods in Low Back Pain © Open Medical Institute 2020 SPEAKERS AND TOPICS Peter Marhofer, MD Professor of Anesthesia and Intensive Care Medicine Department of Anesthesia and Intensive Care Medicine Medical University of Vienna Vienna Austria • Principles of Regional Anaesthesia I • Principles of Regional Anaesthesia II • Ultrasound in Anaesthesia and Intensive Care Medicine I • Ultrasound in Anaesthesia and Intensive Care Medicine II Rohan Panchamia, MD Assistant Professor of Clinical Anesthesiology Weill Cornell Medical College Assistant Attending -
Clinical Pharmacy Specialist
SAMPLE JOB DESCRIPTION Clinical Pharmacist Specialist I. JOB SUMMARY The Clinical Pharmacist Specialists are responsible and accountable for the provision of safe, effective, and prompt medication therapy. Through various assignments within the department, they provide support of centralized and decentralized medication-use systems as well as deliver optimal medication therapy to patients with a broad range of disease states. Clinical Pharmacist Specialists proficiently provide direct patient-centered care and integrated pharmacy operational services in a decentralized practice setting with physicians, nurses, and other hospital personnel. These clinicians are aligned with target interdisciplinary programs and specialty services to deliver medication therapy management within specialty patient care services and to ensure pharmaceutical care programs are appropriately integrated throughout the institution. In these clinical roles, Clinical Pharmacist Specialists participate in all necessary aspects of the medication-use system while providing comprehensive and individualized pharmaceutical care to the patients in their assigned areas. Pharmaceutical care services include but are not limited to assessing patient needs, incorporating age and disease specific characteristics into drug therapy and patient education, adjusting care according to patient response, and providing clinical interventions to detect, mitigate, and prevent medication adverse events. Clinical Pharmacist Specialists serve as departmental resources and liaisons to other -
COVID-19 Pneumonia: Different Respiratory Treatment for Different Phenotypes? L
Intensive Care Medicine EDITORIAL Un-edited accepted proof COVID-19 pneumonia: different respiratory treatment for different phenotypes? L. Gattinoni1, D. Chiumello2, P. Caironi3, M. Busana1, F. Romitti1, L. Brazzi4, L. Camporota5 Affiliations: 1Department of Anesthesiology and Intensive Care, Medical University of GöttinGen 4Department of Anesthesia, Intensive Care and Emergency - 'Città della Salute e della Scienza’ Hospital - Turin 5Department of Adult Critical Care, Guy’s and St Thomas’ NHS Foundation Trust, Health Centre for Human and Applied Physiological Sciences - London Corresponding author: Luciano Gattinoni Department of Anesthesiology and Intensive Care, Medical University of Göttingen, Robert-Koch Straße 40, 37075, Göttingen, Germany Conflict of interests: The authors have no conflict of interest to disclose NOTE: This article is the pre-proof author’s accepted version. The final edited version will appear soon on the website of the journal Intensive Care Medicine with the following DOI number: DOI 10.1007/s00134-020-06033-2 1 Gattinoni L. et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? (2020) Intensive Care Medicine; DOI: 10.1007/s00134-020-06033-2 Intensive Care Medicine EDITORIAL Un-edited accepted proof The Surviving Sepsis CampaiGn panel (ahead of print, DOI: 10.1007/s00134-020-06022-5) recently recommended that “mechanically ventilated patients with COVID-19 should be managed similarly to other patients with acute respiratory failure in the ICU.” Yet, COVID-19 pneumonia [1], despite falling in most of the circumstances under the Berlin definition of ARDS [2], is a specific disease, whose distinctive features are severe hypoxemia often associated with near normal respiratory system compliance (more than 50% of the 150 patients measured by the authors and further confirmed by several colleagues in Northern Italy). -
Pharmacist-Physician Team Approach to Medication-Therapy
Pharmacist-Physician Team Approach to Medication-Therapy Management of Hypertension The following is a synopsis of “Primary-Care-Based, Pharmacist-Physician Collaborative Medication-Therapy Management of Hypertension: A Randomized, Pragmatic Trial,” published online in June 2014 in Clinical Therapeutics. What is already known on this topic? found that the role of the pharmacist differed within each study; whereas some pharmacists independently initiated and High blood pressure, also known as hypertension, is a changed medication therapy, others recommended changes major risk factor for cardiovascular disease, the leading to physicians. Pharmacists were already involved in care in all cause of death for U.S. adults. Helping patients achieve but one study. blood pressure control can be difficult for some primary care providers (PCPs), and this challenge may increase with After reviewing the RCTs, the authors conducted a randomized the predicted shortage of PCPs in the United States by 2015. pragmatic trial to investigate the processes and outcomes that The potential shortage presents an opportunity to expand result from integrating a pharmacist-physician team model. the capacity of primary care through pharmacist-physician Participants were randomly selected to receive PharmD-PCP collaboration for medication-therapy management (MTM). MTM or usual care from their PCPs. The authors conducted MTM performed through a collaborative practice agreement the trial within a university-based internal medicine medical allows pharmacists to initiate and change medications. group where the collaborative PharmD-PCP MTM team Researchers have found positive outcomes associated included an internal medicine physician and two clinical with having a pharmacist on the care team; however, the pharmacists, both with a Doctor of Pharmacy degree, at least evidence is limited to only a few randomized controlled 1 year of pharmacy practice residency training, and more than trials (RCTs). -
Intensive Care Medicine in 10 Years
BOOKS,FILMS,TAPES &SOFTWARE are difficult to read, the editing is inconsis- tory for critical care medicine. The book is initiate a planning process for leaders who tent, and the content that was omitted indi- divided into sections entitled “Setting the recognize the imperative for change and ad- cates that “efforts to bring this work from Stage,” “Diagnostic, Therapeutic, and In- aptation in critical care. Accordingly, I rec- conception to fruition in less than one year” formation Technologies 10 Years From ommend this book to individuals and groups (as stated in the book’s acknowledgments Now,” “How Might Critical Care Medicine engaged in all aspects of critical care man- section) prevented this book from being a Be Organized and Regulated?” “Training,” agement, now and in the future. “gold standard” text. and “The Critical Care Agenda.” Each sec- J Christopher Farmer MD tion consists of a series of essays/chapters Marie E Steiner MD MSc Department of Medicine that discuss various aspects of the topic, and Department of Pediatrics Mayo Clinic all the sections have solid scientific support Divisions of Pulmonary/ Rochester, Minnesota and bibliographies. The individual topics Critical Care and Hematology/ span the entire range of critical-care clinical Oncology/Blood and Marrow The author reports no conflict of interest related practice, administration, quality and safety, Transplantation to the content of this book review. and so forth. The contributors are acknowl- University Children’s Hospital, Fairview edged senior clinical and scientific leaders University of Minnesota Mechanical Ventilation: Physiological in critical care medicine from around the Minneapolis, Minnesota and Clinical Applications, 4th edition. -
Intravenous Immunoglobulin Fails to Improve ARDS in Patients
Prohaska et al. Journal of Intensive Care (2018) 6:11 DOI 10.1186/s40560-018-0278-8 RESEARCH Open Access Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy Stefanie Prohaska1, Andrea Schirner1, Albina Bashota1, Andreas Körner1, Gunnar Blumenstock2 and Helene A. Haeberle1* Abstract Background: Acute respiratory distress syndrome (ARDS) is associated with high mortality rates. ARDS patients suffer from severe hypoxemia, and extracorporeal membrane oxygenation (ECMO) therapy may be necessary to ensure oxygenation. ARDS has various etiologies, including trauma, ischemia-reperfusion injury or infections of various origins, and the associated immunological responses may vary. To support the immunological response in this patient collective, we used intravenous IgM immunoglobulin therapy to enhance the likelihood of pulmonary recovery. Methods: ARDS patients admitted to the intensive care unit (ICU) who were placed on ECMO and treated with (IVIG group; n = 29) or without (control group; n = 28) intravenous IgM-enriched immunoglobulins for 3 days in the initial stages of ARDS were analyzed retrospectively. Results: The baseline characteristics did not differ between the groups, although the IVIG group showed a significantly reduced oxygenation index compared to the control group. We found no differences in the length of ICU stay or ventilation parameters. We did not find a significant difference between the groups for the extent of inflammation or for overall survival. Conclusion: We conclude that administration -
ASHP Statement on Pharmaceutical Care
Medication Therapy and Patient Care: Organization and Delivery of Services–Statements 331 ASHP Statement on Pharmaceutical Care The purpose of this statement is to assist pharmacists in under- Care. Central to the concept of care is caring, a personal standing pharmaceutical care. Such understanding must pre- concern for the well-being of another person. Overall cede efforts to implement pharmaceutical care, which ASHP patient care consists of integrated domains of care including believes merit the highest priority in all practice settings. (among others) medical care, nursing care, and pharmaceu- Possibly the earliest published use of the term pharma- tical care. Health professionals in each of these disciplines ceutical care was by Brodie in the context of thoughts about possess unique expertise and must cooperate in the patient’s drug use control and medication-related services.1,2 It is a overall care. At times, they share in the execution of the various term that has been widely used and a concept about which types of care (including pharmaceutical care). To pharma- much has been written and discussed in the pharmacy pro- ceutical care, however, the pharmacist contributes unique fession, especially since the publication of a paper by Hepler knowledge and skills to ensure optimal outcomes from the and Strand in 1990.3–5 ASHP has formally endorsed the con- use of medications. cept.6 With varying terminology and nuances, the concept At the heart of any type of patient care, there exists a has also been acknowledged by other national pharmacy or- one-to-one relationship between a caregiver and a patient. -
Intensive Care Units (ICU): the Clinical Pharmacist Role to Improve Clinical Outcomes and Reduce Mortality Rate- an Undeniable Function
Open Access Journal of Clinical Intensive Care and Medicine Review Article Intensive Care Units (ICU): The clinical pharmacist role to improve clinical ISSN 2639-6653 outcomes and reduce mortality rate- An undeniable function Luisetto M1* and Ghulam Rasool Mashori2 1Applied Pharmacologist, Hospital Pharmacist Manager 29121, Italy 2Professor & Director, Peoples University of Medcial & Health Sciences for Woman, Nawabshah, Pakistan *Address for Correspondence: Luisetto M, Applied Abstract Pharmacologist, Hospital Pharmacist Manager 29121, Italy, Email: [email protected] Observing relevant biomedical literature we have see that clinical pharmacist play a crucial role in ICU Submitted: 09 October 2017 settings with reducing in mortality rate and improving some clinical outcomes. Approved: 01 November 2017 Published: 02 November 2017 Copyright: 2017 Luisetto M, et al. This is Introduction an open access article distributed under the Creative Commons Attribution License, which In ICU settings we can easily observe that the mortality rate is higher then other permits unrestricted use, distribution, and wards and for this reason a real multisiciplinatity medical team with added clinical ph. reproduction in any medium, provided the Competences can improve this situation. High intensity of cure, polipharmacy, critical original work is properly cited. patient conditions need also a pharmaceutical competencies to be added to the classic Keywords: ICU; Clinical pharmacy; Pharmaceutical decision making systems (clinical- managerial). The critically hill patients need a more care; Clinical outcomes; Mortality rate rational decision making systems to improve the clinical outcomes and in safety way. Material and Methods In this review and research paper we have searched some relevant biomedical literature in order to evaluate the real eficacy of clinical pharmacist in improving clinical outcomes and reducing mortality rate. -
Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19—A Retrospective Study
Journal of Clinical Medicine Article Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19—A Retrospective Study Kevin Roedl 1,* , Gerold Söffker 1, Dominic Wichmann 1 , Olaf Boenisch 1, Geraldine de Heer 1 , Christoph Burdelski 1, Daniel Frings 1, Barbara Sensen 1, Axel Nierhaus 1 , Dirk Westermann 2, Stefan Kluge 1 and Dominik Jarczak 1 1 Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (G.S.); [email protected] (D.W.); [email protected] (O.B.); [email protected] (G.d.H.); [email protected] (C.B.); [email protected] (D.F.); [email protected] (B.S.); [email protected] (A.N.); [email protected] (S.K.); [email protected] (D.J.) 2 Department of Interventional and General Cardiology, University Heart Centre Hamburg, 20246 Hamburg, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-40-7410-57020 Abstract: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the coron- avirus disease 2019 (COVID-19) led to an ongoing pandemic with a surge of critically ill patients. Very little is known about the occurrence and characteristic of cardiac arrest in critically ill patients Citation: Roedl, K.; Söffker, G.; with COVID-19 treated at the intensive care unit (ICU). The aim was to investigate the incidence Wichmann, D.; Boenisch, O.; de Heer, and outcome of intensive care unit cardiac arrest (ICU-CA) in critically ill patients with COVID-19. G.; Burdelski, C.; Frings, D.; Sensen, This was a retrospective analysis of prospectively recorded data of all consecutive adult patients B.; Nierhaus, A.; Westermann, D.; with COVID-19 admitted (27 February 2020–14 January 2021) at the University Medical Centre et al. -
Telepharmacy Rules and Statutes: a 50-State Survey
American Journal of Medical Research 5(2), 2018 pp. 7–23, ISSN 2334-4814, eISSN 2376-4481 doi:10.22381/AJMR5220181 TELEPHARMACY RULES AND STATUTES: A 50-STATE SURVEY GEORGE TZANETAKOS Department of Health Management and Policy, College of Public Health, The University of Iowa FRED ULLRICH Department of Health Management and Policy, College of Public Health, The University of Iowa KEITH MUELLER [email protected] Department of Health Management and Policy, College of Public Health, The University of Iowa (corresponding author) ABSTRACT. There has been a significant decline in the number of independently owned rural pharmacies serving non-metropolitan areas, thereby limiting access to pharmaceutical services for rural residents, particularly for those most vulnerable and in need of these services. The use of telepharmacy is one potential solution to this problem. Telepharmacies deliver pharmaceutical care to outpatients at a distance via telecommunication and other advanced technologies. This study identifies rules and laws enacted by states authorizing the use of community telepharmacy initiatives within their respective jurisdictions. As of August 2016, the use of telepharmacy was authorized, in varying capacities, in 23 states (46%). Pilot program development that could apply to telepharmacy initiatives was authorized by six states (12%). Waivers to administrative or legislative pharmacy practice requirements that could allow for telepharmacy initiatives were permitted in five states (10%). Nearly one-third of the states (16, or 32%) did not authorize the use of telepharmacy, nor did they authorize the pursuit of telepharmacy initiatives via pilot programs or waivers. Keywords: telepharmacy; rule; statute; rural; community; outpatient How to cite: Tzanetakos, George, Fred Ullrich, and Keith Mueller (2018). -
Specialty Pharmacy Drug List
Specialty Pharmacy Drug List Our Specialty Pharmacy provides patients with comprehensive support services and coordinated delivery related to high-cost oral, inhaled or injectable specialty medications, used to treat complex conditions. We are your single source for high-touch patient care management to control side effects, patient support and education to ensure compliance or continued treatment, and specialized handling and distribution of medications directly to the patient or care provider. Specialty medications may be covered under either the medical or pharmacy benefit. Please consult your insurance documentation to determine which benefit covers these medications. We offer a broad specialty medication list containing nearly 500 drugs, covering 42 therapeutic categories and specialty disease states. This list is updated with new information each quarter. Characteristics of Specialty Medications “Specialty” medications are defined as high-cost oral or injectable medications used to treat complex chronic conditions. These are highly complex medications, typically biology-based, that structurally mimic compounds found within the body. High-touch patient care management is usually required to control side effects and ensure compliance. Specialized handling and distribution are also necessary to ensure appropriate medication administration. Medications must have at least one of the following characteristics in order to be classified as a specialty medication by Magellan Rx Management. High Cost High Complexity High Touch High-cost medications -
Rapid Evidence Review
Rapid Evidence Review Clinical evidence for the use of intravenous immunoglobulin in the treatment of COVID- 19 Version 2, 14th May 2020 1 Prepared by the COVID-19 Evidence Review Group with clinical contribution from Dr. Niall Conlon, Consultant Immunologist, St. James Hospital, Dr. Mary Keogan, Clinical Lead National Clinical Programme for Pathology & Consultant Immunologist, Beaumont Hospital. Key changes between version 1 and version 2 (14th May 2020) A number of case reports describing the use of IVIG are included in this version and 2 additional studies which focused specifically on the use of IVIG in patients with COVID-19 – one case series and one retrospective cohort study (available as a pre-print). A number of guidelines have included a reference to IVIG, but the general consensus is not to use IVIG. The recent reports of Kawasaki Disease in children with COVID-19 highlight the role of IVIG and aspirin to treat this condition and supporting evidence of its benefit are available from 2 case reports and one case series. The COVID-19 Evidence Review Group for Medicines was established to support the HSE in managing the significant amount of information on treatments for COVID-19. This COVID-19 Evidence Review Group is comprised of evidence synthesis practitioners from across the National Centre for Pharmacoeconomics (NCPE), Medicines Management Programme (MMP) and the National Medicines Information Centre (NMIC). The group respond to queries raised via the Office of the CCO, National Clinical Programmes and the Department of Health and respond in a timely way with the evidence review supporting the query.